Caisse DE Depot ET Placement DU Quebec Increases Stock Position in Edwards Lifesciences Co. (NYSE:EW)

Caisse DE Depot ET Placement DU Quebec grew its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 56.7% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 82,974 shares of the medical research company’s stock after purchasing an additional 30,038 shares during the quarter. Caisse DE Depot ET Placement DU Quebec’s holdings in Edwards Lifesciences were worth $5,475,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Cetera Advisors LLC boosted its stake in Edwards Lifesciences by 175.1% during the 1st quarter. Cetera Advisors LLC now owns 38,090 shares of the medical research company’s stock worth $3,640,000 after purchasing an additional 24,242 shares during the period. GAMMA Investing LLC boosted its stake in shares of Edwards Lifesciences by 30.5% during the second quarter. GAMMA Investing LLC now owns 3,375 shares of the medical research company’s stock worth $312,000 after buying an additional 788 shares during the period. Mather Group LLC. grew its holdings in shares of Edwards Lifesciences by 55.6% during the second quarter. Mather Group LLC. now owns 5,070 shares of the medical research company’s stock worth $484,000 after buying an additional 1,811 shares during the last quarter. Kingswood Wealth Advisors LLC increased its position in Edwards Lifesciences by 5.5% in the 2nd quarter. Kingswood Wealth Advisors LLC now owns 13,450 shares of the medical research company’s stock valued at $1,242,000 after acquiring an additional 696 shares during the period. Finally, Park Avenue Securities LLC raised its stake in Edwards Lifesciences by 0.5% during the 2nd quarter. Park Avenue Securities LLC now owns 23,484 shares of the medical research company’s stock valued at $2,169,000 after acquiring an additional 108 shares during the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Insider Activity

In other news, insider Larry L. Wood sold 25,000 shares of the company’s stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the completion of the transaction, the insider now owns 198,526 shares of the company’s stock, valued at $13,084,848.66. This represents a 11.18 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $69.51, for a total transaction of $347,550.00. Following the transaction, the vice president now owns 46,936 shares in the company, valued at approximately $3,262,521.36. The trade was a 9.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 40,000 shares of company stock valued at $2,657,000 over the last 90 days. Insiders own 1.29% of the company’s stock.

Edwards Lifesciences Stock Performance

Edwards Lifesciences stock opened at $70.53 on Tuesday. Edwards Lifesciences Co. has a fifty-two week low of $58.93 and a fifty-two week high of $96.12. The company has a market capitalization of $41.60 billion, a price-to-earnings ratio of 10.18, a PEG ratio of 4.01 and a beta of 1.12. The stock has a fifty day moving average of $68.10 and a two-hundred day moving average of $75.05. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, hitting analysts’ consensus estimates of $0.67. The firm had revenue of $1.35 billion during the quarter, compared to analysts’ expectations of $1.57 billion. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The firm’s quarterly revenue was up 8.9% compared to the same quarter last year. During the same quarter last year, the business posted $0.59 EPS. On average, analysts anticipate that Edwards Lifesciences Co. will post 2.57 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have weighed in on EW shares. Wells Fargo & Company lowered their target price on Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating on the stock in a research note on Monday, September 9th. Barclays raised their target price on shares of Edwards Lifesciences from $85.00 to $88.00 and gave the stock an “overweight” rating in a research note on Monday. Piper Sandler cut their price target on shares of Edwards Lifesciences from $73.00 to $70.00 and set a “neutral” rating for the company in a report on Friday, October 25th. Royal Bank of Canada raised their price objective on shares of Edwards Lifesciences from $75.00 to $80.00 and gave the company an “outperform” rating in a research report on Wednesday, November 27th. Finally, Daiwa America cut Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 30th. Seventeen research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $77.25.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.